EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Alamandine: Potential Protective Effects in SARS-CoV-2 Patients

Ava Soltani Hekmat iD, Kazem Javanmardi iD

Journal of the Renin-Angiotensin-Aldosterone System · 2021-01 · 2021

DOI: 10.1155/2021/6824259 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the Renin-Angiotensin-Aldosterone System, online erschienen am 08.11.2021. Verfasst von Ava Soltani Hekmat und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Fasa University of Medical Sciences, Fasa, Iran. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID-19) can occur due to contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has no confined treatment and, consequently, has high hospitalization and mortality rates. Moreover, people who contract COVID-19 present systemic inflammatory spillover. It is now known that COVID-19 pathogenesis is linked to the renin-angiotensin system (RAS). COVID-19 invades host cells via the angiotensin-converting enzyme 2 (ACE2) receptor—as such, an individual’s susceptibility to COVID-19 increases alongside the upregulation of this receptor. COVID-19 has also been associated with interstitial pulmonary fibrosis, which leads to acute respiratory distress, cardiomyopathy, and shock. These outcomes are thought to result from imbalances in angiotensin (Ang) II and Ang-(1-7)/alamandine activity. ACE2, Ang-(1-7), and alamandine have potent anti-inflammatory properties, and some SARS-CoV-2 patients exhibit high levels of ACE2 and Ang-(1-7). This phenomenon could indicate a failing physiological response to prevent or reduce the severity of inflammation-mediated pulmonary injuries. Alamandine, which is another protective component of the RAS, has several health benefits owing to its antithrombogenic, anti-inflammatory, and antifibrotic characteristics. Alamandine alleviates pulmonary fibrosis via the Mas-related G protein-coupled receptor D (MrgD). Thus, a better understanding of this pathway could uncover novel pharmacological strategies for altering proinflammatory environments within the body. Following such strategies could inhibit fibrosis after SARS-CoV-2 infection and, consequently, prevent COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentAngiotensin IAngiotensin IIAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAnimalsAntiviral AgentsCOVID-19HumansOligopeptidesPeptide FragmentsRenin-Angiotensin System

Substanzen

Angiotensin-Converting Enzyme InhibitorsAntiviral AgentsOligopeptidesPeptide FragmentsalamandineAngiotensin IIAngiotensin IACE2 protein, humanAngiotensin-Converting Enzyme 2angiotensin I (1-7)

Autor:innen und Institutionen

  • Department of Physiology, Fasa University of Medical Sciences, Fasa, Iran.

ORCID-Profile: Ava Soltani Hekmat, Kazem Javanmardi

Zitieren

APA

Soltani Hekmat, A., & Javanmardi, K. (2021). Alamandine: Potential Protective Effects in SARS-CoV-2 Patients. Journal of the Renin-Angiotensin-Aldosterone System, 2021. https://doi.org/10.1155/2021/6824259

Vancouver

Soltani Hekmat A, Javanmardi K. Alamandine: Potential Protective Effects in SARS-CoV-2 Patients. Journal of the Renin-Angiotensin-Aldosterone System. 2021;2021. doi:10.1155/2021/6824259

BibTeX
@article{SoltaniHekmat2021,
  author = {Soltani Hekmat, Ava and Javanmardi, Kazem},
  title = {Alamandine: Potential Protective Effects in SARS-CoV-2 Patients},
  journal = {Journal of the Renin-Angiotensin-Aldosterone System},
  year = {2021},
  volume = {2021},
  doi = {10.1155/2021/6824259}
}
Kostenlos starten →